Avacta opens phase 1 trial for conjugate's efficacy regarding tumours
(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More
| Price | 67.00p on 19-03-2026 at 09:05:36 |
|---|---|
| Change | -2.50p -3.6% |
| Buy | 68.00p |
| Sell | 66.00p |
| Last Trade: | Buy 1,496.00 at 67.125p |
| Day's Volume: | 318,395 |
| Last Close: | 69.50p |
| Open: | 69.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 67.00p - 69.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £293.21m |
| VWAP: | 67.54466p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 1,496 | 67.125p | Ordinary |
09:05:34 - 19-Mar-26 |
| Buy* | 260 | 68.00p | Ordinary |
09:04:48 - 19-Mar-26 |
| Buy* | 6,113 | 67.98p | Ordinary |
09:04:30 - 19-Mar-26 |
| Buy* | 12,922 | 68.00p | Ordinary |
09:03:24 - 19-Mar-26 |
| Buy* | 286 | 68.00p | SI Trade |
09:02:54 - 19-Mar-26 |
| Buy* | 34 | 68.00p | Ordinary |
09:01:38 - 19-Mar-26 |
| Buy* | 18,146 | 67.845p | Ordinary |
09:00:23 - 19-Mar-26 |
| Buy* | 7,500 | 67.7466p | Ordinary |
08:59:46 - 19-Mar-26 |
| Buy* | 19,707 | 67.75p | Ordinary |
08:56:27 - 19-Mar-26 |
| Buy* | 5,000 | 67.015p | Ordinary |
08:49:00 - 19-Mar-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 24th Feb 2026 7:00 am | RNS | PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am | RNS-R | Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am | RNS | Appointment of CSO |
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |